Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke
In patients with severe hypertension, chronic heart failure or a history of stroke, the lower limit of autoregulation of cerebral blood flow (CBF) is shifted to higher levels of blood pressure (BP) than those observed in healthy subjects. The aim of pharmacotherapy for hypertensive patients with an impaired autoregulation of CBF should be to reduce BP while preserving an appropriate CBF. In the present study, 16 hypertensive patients who had had an episode of stroke more than 4 weeks previously were administered the angiotensin II (AT1) receptor antagonist losartan at daily doses of 25-100 mg for 4 weeks. Systolic and diastolic blood pressures were recorded for 24 h using an ambulatory BP monitoring system. CBF in both hemispheres of the cerebrum and cerebellum was quantified using single photon emission tomography with N-isopropyl-p-[123I]iodoamphetamine. At baseline, CBF was 29.7 +/- 6.7 ml/min/100 g in the cerebrum and 31.5 +/- 7.5 ml/min/100 g in the cerebellum. At the end of treatment, BP was lower, while CBF increased by 7.7% in the cerebrum, and remained at the baseline level in the cerebellum. Thus, CBF was preserved despite the reduction in BP. We consider the use of losartan is advantageous for hypertensive patients with a history of stroke in whom autoregulation of CBF is potentially impaired.
| Errataetall: |
CommentIn: J Hum Hypertens. 2004 Oct;18(10):685-6. - PMID 15129231 |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of human hypertension - 18(2004), 10 vom: 07. Okt., Seite 693-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moriwaki, H [VerfasserIn] |
|---|
| Themen: |
Angiotensin II Type 1 Receptor Blockers |
|---|
| Anmerkungen: |
Date Completed 01.02.2005 Date Revised 24.11.2016 published: Print CommentIn: J Hum Hypertens. 2004 Oct;18(10):685-6. - PMID 15129231 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM148201911 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM148201911 | ||
| 003 | DE-627 | ||
| 005 | 20231223045044.0 | ||
| 007 | tu | ||
| 008 | 231223s2004 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0494.xml |
| 035 | |a (DE-627)NLM148201911 | ||
| 035 | |a (NLM)15129230 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moriwaki, H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2005 | ||
| 500 | |a Date Revised 24.11.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Hum Hypertens. 2004 Oct;18(10):685-6. - PMID 15129231 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In patients with severe hypertension, chronic heart failure or a history of stroke, the lower limit of autoregulation of cerebral blood flow (CBF) is shifted to higher levels of blood pressure (BP) than those observed in healthy subjects. The aim of pharmacotherapy for hypertensive patients with an impaired autoregulation of CBF should be to reduce BP while preserving an appropriate CBF. In the present study, 16 hypertensive patients who had had an episode of stroke more than 4 weeks previously were administered the angiotensin II (AT1) receptor antagonist losartan at daily doses of 25-100 mg for 4 weeks. Systolic and diastolic blood pressures were recorded for 24 h using an ambulatory BP monitoring system. CBF in both hemispheres of the cerebrum and cerebellum was quantified using single photon emission tomography with N-isopropyl-p-[123I]iodoamphetamine. At baseline, CBF was 29.7 +/- 6.7 ml/min/100 g in the cerebrum and 31.5 +/- 7.5 ml/min/100 g in the cerebellum. At the end of treatment, BP was lower, while CBF increased by 7.7% in the cerebrum, and remained at the baseline level in the cerebellum. Thus, CBF was preserved despite the reduction in BP. We consider the use of losartan is advantageous for hypertensive patients with a history of stroke in whom autoregulation of CBF is potentially impaired | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiotensin II Type 1 Receptor Blockers |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Iofetamine |2 NLM | |
| 650 | 7 | |a C2A5X08042 |2 NLM | |
| 650 | 7 | |a Losartan |2 NLM | |
| 650 | 7 | |a JMS50MPO89 |2 NLM | |
| 700 | 1 | |a Uno, H |e verfasserin |4 aut | |
| 700 | 1 | |a Nagakane, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashida, K |e verfasserin |4 aut | |
| 700 | 1 | |a Miyashita, K |e verfasserin |4 aut | |
| 700 | 1 | |a Naritomi, H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of human hypertension |d 1996 |g 18(2004), 10 vom: 07. Okt., Seite 693-9 |w (DE-627)NLM012646121 |x 1476-5527 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2004 |g number:10 |g day:07 |g month:10 |g pages:693-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2004 |e 10 |b 07 |c 10 |h 693-9 | ||